Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Free Cash Flow (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Free Cash Flow data on record, last reported at $5.5 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 207.45% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $54.9 million, up 488.01%, while the annual FY2025 figure was $54.9 million, 488.01% up from the prior year.
  • Free Cash Flow reached $5.5 million in Q4 2025 per MIRM's latest filing, down from $39.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $39.5 million in Q3 2025 and bottomed at -$40.2 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$13.0 million, with a median of -$17.8 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: tumbled 135.81% in 2021, then soared 938.5% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$33.2 million in 2021, then decreased by 4.11% to -$34.5 million in 2022, then surged by 51.85% to -$16.6 million in 2023, then skyrocketed by 69.38% to -$5.1 million in 2024, then soared by 207.45% to $5.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $5.5 million in Q4 2025, $39.5 million in Q3 2025, and $11.9 million in Q2 2025.